John Maher

John Maher


  • Phone020 7188 7188
  • 3rd Floor
    CAR Mechanics Group
    Bermondsey Wing

    United Kingdom

  • 5666

Personal profile

Research interests


 The overall goal of my research activity is the development of cellular immunotherapy for malignancy. Currently, I lead the “CAR Mechanics” research group, which consists of 1 MRC funded iclinician scientist, 3 post-doctoral research fellows, 3 non-clinical PhD students, 3 technicians, in additin to regular MRes, MSc and BSc students.

A major focus of our work entails the design and testing of genetically delivered “Chimeric Antigen Receptors” (CAR) to re-target T-cell specificity against designated native tumour antigens. My research group has generated CARs with specificity against prostate-specific membrane antigen, MUC1, ErbB2, the extended ErbB kinase family, the epithelial-specific integrin avb6, the receptor for CSF-1, the receptor for IL-3, IGF-1 receptor and CD19. Projects are focused upon pre-clinical testing of these molecules in models of several malignancies, including breast cancer, ovarian cancer, malignant mesothelioma, prostate cancer, selected lymphomas, acute myeloid leukaemia and pancreatic cancer. We collaborate with several groups at King’s College London (Imaging, Immunobiology, Haematological Oncology, Head & Neck Cancer, Breast Cancer, Novel vectors for gene transfer), St Bartholomew’s Hospital (Imaging) and Imperial College London (Gynaecological Oncology, Haematology).


Our first clinical trial of CAR-based immunotherapy was initiated in 2015 in patients with recurrent head and neck cancer. Twleve patients have now been treated on this study.

We also work on the development of adoptive immunotherapy using ex-vivo expanded gd T-cells and collaborate with a group based in the Shaare Zedek Medical Center, Jerusalem, Israel who produce liposomal amino-bisphosphonates which can be used to potentiate this therapeutic approach. 

Some other studies involving tumour immunology are also undertaken in our group, primarily focused upon the measurement of tumour-specific effector molecules and cells and the assessment of possible targets or other molecules that may be exploited using cellular immunotherapy.

Recently developed proprietary CAR technologies developed by the group have been patented and will be developed through a spin out company named Leucid Bio.

Research interests (short)

Adoptive immunotherapy of cancer using engineered lymphocytes

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being

Education/Academic qualification

Master of Science, University of London

Award Date: 1 Jan 1998

Doctor of Philosophy, University of London

Award Date: 1 Jan 1995

Bachelor of Medicine, Degree is MB BCh BAO (Hons), Trinity College Dublin

Award Date: 1 Jan 1987

Bachelor of Science, Degree is entitled BA Mod, Trinity College Dublin

Award Date: 1 Jan 1984


Dive into the research topics where John Maher is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or